Clinical trial · Observational
Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
NCT06535113CI-TRIAL-00113924Inflamm-AMLrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical Practice | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- acute myeloid leukemia (AML) patients treated in the clinical units
- description
- acute myeloid leukemia (AML) patients treated in the clinical units
- interventionNames
- Other: Clinical Practice
Primary outcomes (1)
- measure
- Inflammasome Activity
- timeFrame
- At diagnosis, in case of treatment failure and at 6 months after first line chemotherapy initiation
- description
- The outcome variable is the inflammasome activation in AML blasts (PB e BM)
Secondary outcomes (1)
- measure
- Correlation Inflammasome and Therapy
- timeFrame
- At diagnosis, in case of treatment failure and at 6 months after first line chemotherapy initiation
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Any gender, * Adults (\>18 years old), * New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria) * Capable of comprehend the study and the consent form, * Willing to sign the informed consent for the study. For the retrospective population we will select: biological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria. Exclusion Criteria: * Pediatric patients (\<18 years old), * Patients unable or unwilling to sign the informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.